Selective estrogen receptor modulators: A controversial approach for managing postmenopausal health

被引:8
作者
Curtis, MG [1 ]
机构
[1] Univ Texas, Dept Obstet Gynecol & Reprod Med, Houston, TX 77026 USA
关键词
D O I
10.1089/jwh.1999.8.321
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Hormone replacement therapy (HRT) is considered the standard of care for managing the acute (e.g., hot flashes, vaginal dryness) and long-term (e.g., increased risk of cardiovascular disease, osteoporosis) sequelae of menopause. A group of synthetic nonsteroidal compounds, which act on the estrogen receptor, have been promoted for use as an alternative to hormonal therapy for postmenopausal women. Originally called antiestrogens because of their ability to antagonize the action of estrogen, these compounds possess both agonist and antagonist properties of estrogen action. They are now referred to as selective estrogen receptor modulators (SERMs). This article reviews the mechanism of action and the efficacy and safety data for SERMs currently used for clinical purposes. These data may indicate why the use of SERMs is a controversial alternative to HRT.
引用
收藏
页码:321 / 333
页数:13
相关论文
共 154 条
[1]  
*AM CANC SOC, 1995, BREAST CANC FACTS FI
[2]  
*AM CANC SOC, 1997, CANC FACTS FIG 1997
[3]   THE TRANSITIONAL YEARS AND BEYOND [J].
ANDREWS, WC .
OBSTETRICS AND GYNECOLOGY, 1995, 85 (01) :1-5
[4]  
[Anonymous], 1992, Lancet, V339, P1
[5]   Activity of raloxifene in immature and ovariectomized rat uterotrophic assays [J].
Ashby, J ;
Odum, J ;
Foster, JR .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1997, 25 (03) :226-231
[6]  
Baker V L, 1996, Obstet Gynecol Surv, V51, P45, DOI 10.1097/00006254-199601000-00021
[7]   PLASMA-LIPOPROTEIN LEVELS AS PREDICTORS OF CARDIOVASCULAR DEATH IN WOMEN [J].
BASS, KM ;
NEWSCHAFFER, CJ ;
KLAG, MJ ;
BUSH, TL .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (19) :2209-2216
[8]  
BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062
[9]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[10]   RALOXIFENE (LY139481 HCL) PREVENTS BONE LOSS AND REDUCES SERUM-CHOLESTEROL WITHOUT CAUSING UTERINE HYPERTROPHY IN OVARIECTOMIZED RATS [J].
BLACK, LJ ;
SATO, M ;
ROWLEY, ER ;
MAGEE, DE ;
BEKELE, A ;
WILLIAMS, DC ;
CULLINAN, GJ ;
BENDELE, R ;
KAUFFMAN, RF ;
BENSCH, WR ;
FROLIK, CA ;
TERMINE, JD ;
BRYANT, HU .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) :63-69